Efficacy and safety of novel carbapenem-β-lactamase inhibitor combinations: imipenem-cilastatin/relebactam results from randomized controlled trials
BackgroundGram-negative bacteria is a global public health problem. Treatment options include novel beta-lactamase inhibitors.ObjectivesThe objective of this study was to collect information on the efficacy and safety of novel β-lactamase inhibitor combinations such as imipenem-cilastatin/relebactam...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2023-12-01
|
| Col·lecció: | Frontiers in Medicine |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1304369/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|